Course Provider
COMPASS Pathways plc (Nasdaq: CMPS) is a UK-headquartered clinical-stage biopharmaceutical company and the most advanced developer of a classic psychedelic medicine. Its lead asset, COMP360 — a synthetic, proprietary formulation of psilocybin — is being developed for treatment-resistant depression (TRD) delivered alongside a psychological-support model. COMP360 is the first psilocybin programme to complete two positive pivotal Phase 3 trials: COMP005 met its primary endpoint in June 2025 and the confirmatory COMP006 (two fixed doses given three weeks apart) did so in February 2026, with 26-week data reported in July 2026 confirming a rapid and durable antidepressant profile. In April 2026 the FDA granted a rolling NDA submission request and selected COMP360 for the Commissioner's National Priority Voucher programme, which carries a shortened review window. COMPASS has since begun that rolling submission and guides to a potential US launch in the first half of 2027, subject to approval, positioning it as the frontrunner for the first FDA-approved classic psychedelic therapy.
Compass Pathways is not a broad psychedelic school so much as a drug-development company with a rigorous therapist-training arm built around its COMP360 psilocybin programme. Its reputation sits in the mainstream clinical-research end of the field: strong on structure, manuals and regulatory alignment, with lineage drawn from psychology, psychiatry and established psychedelic researchers rather than the retreat world. It is best for licensed professionals who want exposure to a highly protocol-driven model tied to trial delivery and eventual healthcare implementation, not for general curiosity or an open-ended introductory course.
Best for licensed clinicians and other healthcare professionals who want training connected to psilocybin treatment delivery in a regulated setting. It also suits research teams and organisations looking for a structured, scalable model rather than an experiential or retreat-style programme.
Compass’s therapist training has been used for clinical research and requires professional qualifications and clinical experience in psychotherapy or mental health counselling. Its post-approval provider training grant call asks applicants to show experience in psychedelic training design, delivery and governance, plus regulatory alignment and the ability to scale.
Compass says its therapist training programme was approved by the FDA for research purposes. It does not publish a single consumer-facing accreditation or CME/CE claim for an open enrolment course.
Compass does not publish a single course price. For its research supply, it states that COMP360 psilocybin is provided to researchers free of charge, while researchers cover packaging and shipping costs; for provider training, Compass launched a grant programme to fund external organisations to create training content for future commercial launch.
Learners are trained in a manualised psilocybin-therapy model covering preparation, in-session support, applied clinical work, mentoring and ongoing professional development. The practical outcome is competency for working within Compass-aligned COMP360 delivery pathways rather than a stand-alone academic credential.
Linked Courses
3
Active Listings
0
Primary Formats
Hybrid, Self-paced
Programs linked directly to this provider in the Blossom course dataset.
By COMPASS Pathways
This page summarises results from COMPASS Pathways' phase 2b trial of investigational COMP360 psilocybin treatment for treatment-resistant depression. The study assessed three doses and reported a significant reduction in depressive symptoms after 25mg with psychological support.
By COMPASS Pathways
The COMPASS Therapist Training Programme provides evidence-based training for mental health professionals working with COMP360 psilocybin therapy. It combines online theory, in-person practical skills training, and ongoing mentoring.
By COMPASS Pathways
An overview of investigational psilocybin therapy and how it is being studied for mental health conditions. It explains the treatment process, including preparation, the dosing session, and integration.
No medicine self-experience listed
Reference points selected from shared training modalities, learner audience, level, delivery format, pricing, and location.